dc.contributor.advisor | Sharmin, Sabrina | |
dc.contributor.author | Tasnim, Jarin | |
dc.date.accessioned | 2024-12-12T08:43:57Z | |
dc.date.available | 2024-12-12T08:43:57Z | |
dc.date.copyright | ©2024 | |
dc.date.issued | 2024-10 | |
dc.identifier.other | ID 20146020 | |
dc.identifier.uri | http://hdl.handle.net/10361/24911 | |
dc.description | This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024. | en_US |
dc.description | Cataloged from PDF version of thesis. | |
dc.description | Includes bibliographical references (pages 48-52). | |
dc.description.abstract | In recent years, medical science has acheived a lot of success in the field of treatment.Treating cancer
sucessfully is one of them.But though having unimaginable success and advancement in the medical field the
rate of death due to cancer is increasing day by day with a growing population. According to the World Health
Organization there were about estimated 20 million new cancer cases and 9.7 million deaths in 2022. So it is
very clear that conventional chemotherapy or cancer treatment requires more advanced aproaches in order to
control this growing death rate due to cancer.Application of Cell Penetrating Petides is one of those approaches. One extremely promising method for intracellular medication delivery is the use of cell-penetrating peptides.
Cancer therapy is a pertinent clinical use of cell-penetrating peptides. Both oligonucleotide-based treatments
and traditional small-molecule medications might be more effectively treated by increasing their absorption in
tumor cells using peptide-based delivery.The cancer applications of cell penetrating peptides as delivery
systems are the main focus of this review; including various aspects of drug loading, cargoes, and delivery are
covered along with techniques for targeted delivery,transducible agents coupled to cell-penetrating peptides,
and activatable cell-penetrating peptide.Clinical limitations with strategies to overcome those and comparison
with conventional treatment are also two important aspects of this review. | en_US |
dc.description.statementofresponsibility | Jarin Tasnim | |
dc.format.extent | 62 pages | |
dc.language.iso | en | en_US |
dc.publisher | Brac University | en_US |
dc.rights | Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. | |
dc.subject | Cancer therapy | en_US |
dc.subject | Cell penetrating peptides | en_US |
dc.subject | Chemotherapy | en_US |
dc.subject | Activatable peptides | en_US |
dc.subject | Doxorubicin | en_US |
dc.subject | Paclitaxel | en_US |
dc.subject | Drug delivery | en_US |
dc.subject.lcsh | Peptides--Physiological transport. | |
dc.subject.lcsh | Drug carriers (Pharmacy). | |
dc.subject.lcsh | Cancer--Treatment. | |
dc.subject.lcsh | Drug delivery systems. | |
dc.title | A review: cell penetrating peptides-an advanced drug delivery system & therapeutic approach for the treatment of Cancer | en_US |
dc.type | Thesis | en_US |
dc.contributor.department | School of Pharmacy, Brac University | |
dc.description.degree | B. Pharmacy | |